Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 4/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8836457 | 0.88 | MMP2 (0.41) | MMP9MMP2 | |
| SCHEMBL10765755 | 0.79 | TTR (0.41) | HDAC3 | |
| SCHEMBL7784104 | 0.78 | CA12 (0.43) | MMP9MMP13ADAM17MMP1MMP2 | |
| SCHEMBL12933668 | 0.77 | MMP9 (0.54) | MMP9MMP13ADAM17MMP1MMP2 | |
| SCHEMBL9754526 | 0.77 | MMP9 (0.54) | MMP9MMP13ADAM17MMP1MMP2 | |
| SCHEMBL4509390 | 0.76 | CYP1A2 (0.53) | HDAC3HDAC6HDAC1HDAC2 | |
| SCHEMBL1168298 | 0.75 | MMP2 (0.46) | MMP9MMP2MMP12 | |
| SCHEMBL28046230 | 0.73 | TTR (0.45) | HDAC3 | |
| SCHEMBL4506081 | 0.72 | KYNU (0.44) | GRIK1 | |
| SCHEMBL9318602 | 0.72 | CYSLTR2 (0.42) | MMP9MMP2ALDH1A1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114462-B1 | Compounds for fluorescence imaging | UNIV GENEVE (CH) | 2013-06-05 | — | — | EP | claimed |
| US-20100278745-A1 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (CH) | 2010-11-04 | — | — | US | claimed |
| EP-2114462-A2 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (CH) | 2009-11-11 | — | — | EP | claimed |
| WO-2008078190-A2 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (US) | 2008-07-03 | — | — | WO | claimed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-10345310-B2 | Diagnostic test for early stage cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3307243-A1 | DIAGNOSTIC TEST FOR EARLY STAGE CANCER | The Board of Regents of The University of Texas System (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20170146542-A1 | DIAGNOSTIC TEST FOR EARLY STAGE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2016201064-A1 | DIAGNOSTIC TEST FOR EARLY STAGE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2114462-B1 | Compounds for fluorescence imaging | UNIV GENEVE (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20100278745-A1 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100233782-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | Life Technologies Corporation (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2118129-A2 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | Life Technologies Corporation (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2114462-A2 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090161828-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | LIFE TECHNOLOGIES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080248565-A1 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | INVITROGEN CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008106660-A2 | ISOLATED PHOSPHOLIPID-PROTEIN PARTICLES | INVITROGEN CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008078190-A2 | COMPOUNDS FOR FLUORESCENCE IMAGING | UNIVERSITE DE GENEVE (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | MMP9 2321/4885MMP13 1332/4885ADAM17 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.